Literature DB >> 20020279

Effects of high dose of zoledronic acid on superficial vascular network of membranous bone sites: an intravital study on rat calvarium.

M H Vieillard1, J Paccou, B Cortet, E Biver, J Salleron, G Falgayrac, G Penel.   

Abstract

UNLABELLED: We evaluated the impact of high dose of zoledronic acid on the superficial vascular network parameters of a membranous bone site. During a 5-day follow-up, significant reduction of the vascular density is observed only in the treated group.
INTRODUCTION: The superficial vascularization is of great importance in membranous bone-healing process. A new rat calvarium intravital model was developed to study the short-term effect of a single high dose of zoledronic acid infusion on the superficial vascularization.
METHODS: Optical bone chambers were implanted in the bone tissue surface of Sprague-Dawley rats' calvarium. Nine rats were injected i.v. with 400 µg/kg of zoledronic acid (Z group), and nine rats were injected with vehicle (PSS group). A 5-day follow-up of the vascular network was made by the use of pictures analysis method.
RESULTS: The vascular density significantly decreases only in Z group but there was no significant difference between groups at individual time points. The total length of the vascular network decreases significantly in Z group only (p=0.003) with a significant higher decrease at D3 (p=0.04) and D5 (p=0.02) compared with control. The vascular density related to the smaller vessels (width, 5-10 µm) decreases significantly between T0 and D5 in Z group only (p=0.002).
CONCLUSIONS: With the help of an original intravital animal model a significant modifications on the total length of the vascular network and the vascular density of small vessels are highlighted on a membranous bone site.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20020279     DOI: 10.1007/s00198-009-1146-0

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  31 in total

Review 1.  Biology of bone endothelial cells.

Authors:  E A Streeten; M L Brandi
Journal:  Bone Miner       Date:  1990-08

2.  Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients.

Authors:  Daniele Santini; Bruno Vincenzi; Sara Galluzzo; Fabrizio Battistoni; Laura Rocci; Olga Venditti; Gaia Schiavon; Silvia Angeletti; Federica Uzzalli; Michele Caraglia; Giordano Dicuonzo; Giuseppe Tonini
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

3.  Bisphosphonates and osteonecrosis of the jaw.

Authors:  N G Shenker; A S M Jawad
Journal:  Rheumatology (Oxford)       Date:  2007-05-11       Impact factor: 7.580

4.  Effect of growth hormone and pamidronate on bone blood flow, bone mineral and IGF-I levels in the rat.

Authors:  J Kapitola; J Zák; Z Lacinová; V Justová
Journal:  Physiol Res       Date:  2000       Impact factor: 1.881

5.  Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis.

Authors:  Torsten Hansen; Martin Kunkel; Achim Weber; C James Kirkpatrick
Journal:  J Oral Pathol Med       Date:  2006-03       Impact factor: 4.253

6.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

7.  Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients.

Authors:  Daniele Santini; Bruno Vincenzi; Giordano Dicuonzo; Giuseppe Avvisati; Cristian Massacesi; Fabrizio Battistoni; Michele Gavasci; Laura Rocci; Maria Cristina Tirindelli; Vittorio Altomare; Massimo Tocchini; Maurizio Bonsignori; Giuseppe Tonini
Journal:  Clin Cancer Res       Date:  2003-08-01       Impact factor: 12.531

8.  Effect of pamidronate on bone blood flow in oophorectomized rats.

Authors:  J Kapitola; J Zák
Journal:  Physiol Res       Date:  1998       Impact factor: 1.881

9.  Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.

Authors:  Sundeep Khosla; David Burr; Jane Cauley; David W Dempster; Peter R Ebeling; Dieter Felsenberg; Robert F Gagel; Vincente Gilsanz; Theresa Guise; Sreenivas Koka; Laurie K McCauley; Joan McGowan; Marc D McKee; Suresh Mohla; David G Pendrys; Lawrence G Raisz; Salvatore L Ruggiero; David M Shafer; Lillian Shum; Stuart L Silverman; Catherine H Van Poznak; Nelson Watts; Sook-Bin Woo; Elizabeth Shane
Journal:  J Bone Miner Res       Date:  2007-10       Impact factor: 6.741

Review 10.  Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel.

Authors:  M Aapro; P A Abrahamsson; J J Body; R E Coleman; R Colomer; L Costa; L Crinò; L Dirix; M Gnant; J Gralow; P Hadji; G N Hortobagyi; W Jonat; A Lipton; A Monnier; A H G Paterson; R Rizzoli; F Saad; B Thürlimann
Journal:  Ann Oncol       Date:  2007-09-28       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.